# Lowe (1989) — "Risk Assessment and the Credibility of Federal Regulatory Policy: An FDA Perspective"

*Mary Frances Lowe (Food and Drug Administration), **Regul. Toxicol. Pharmacol.** 9(2):131–141 (1989); presented
5 Nov 1987 at "Environmental Risk Management: Strategies for Industry," Washington DC. DOI
10.1016/0273-2300(89)90030-5. Local: `papers/lateral/lowe1989_rtp_risk-assessment-credibility-fda-perspective.pdf`
(+`.txt`). Operator drop 2026-06-11; READ IN FULL 2026-06-13. *(The PDF was originally dropped under a
download-tool filename containing "Anna's Archive" — a naming artifact, **not** the source; properly sourced.
Renamed to the project convention 2026-06-13.)*
**Grade: [CONFIRMED-primary]** (as read). Register **H27**.

## What it is
The **institutional voice of the de minimis turn**, published in the *same RTP volume and year* as Frawley's own
"Our sacred food — a perspective" (register A4). An FDA staffer's open defense of "**a common sense *de minimis*
interpretation of the 'Delaney clause'**" — and a window onto the *Public Citizen v. Young* defeat the month
before publication.

## Verbatim (with `.txt` line locators)
- The thesis, from the abstract: FDA's food-safety evolution includes "most recently, **a common sense *de
  minimis* interpretation of the 'Delaney clause.'**" (ll. 22–23)
- Cites the SOM rule (register H25) by name — Ref. 8: "Sponsored compounds in food-producing animals… **52 Fed.
  Reg. 49572–49590**" — and the "constituents/impurities" policy (Ref. 9, 47 FR 14464). (ll. 466–472)
- Narrates the **Public Citizen v. Young (1987)** setback in real time: the D.C. Circuit decided "**with some
  reluctance**" that Delaney "did not permit a *de minimis* interpretation," yet "accepted the validity of risk
  assessment" and that "it seems all together correct to characterize… as **trivial**" the color-additive risks
  — "D&C Red No. 19 at between zero and **one in 9 million**, and D&C Orange No. 17 at between zero and **one in
  19 billion**." Congress was "**extraordinarily rigid**," but that was "**at least a comprehensible policy
  choice.**" (ll. 345–361, 478–484)
- The over-conservatism argument (Frawley's, in FDA's mouth): stacking "**worst-case assumption upon worst-case
  assumption**" leaves "the realm of reality"; un-refined assumptions make policy "**rely on assessments based
  on extremely conservative assumptions that will… overestimate risk, perhaps by many orders of magnitude.**"
  (ll. 220–223, 388–391)
- Lists the untested risk-assessment assumptions (from NCTR's Ronald Hart), including that "**a linearized
  multistage model can be used for low-dose extrapolation (hard, perhaps practically impossible, to test).**"
  (ll. 197–205) — the Crump-1976 default (H26), conceded as faith.
- The **Dingell/procedural pole** in FDA's own words: the 1985 CCERP report's principle (iv) — "to develop
  procedures designed to **facilitate scientific inquiry into regulatory matters… in lieu of formal legal-type
  procedures.**" (ll. 281–285)

## Why it matters
- Confirms, from inside FDA and in the open literature, that the "de minimis interpretation of Delaney" was
  *agency policy*, not just industry advocacy — and dates it precisely to the *Public Citizen v. Young* moment.
  Directly augments `10_DE_MINIMIS_LEGAL_LINEAGE.md` (Williams's "with some reluctance" opinion, the trivial-risk
  numbers, the "comprehensible policy choice").
- Places **Frawley's argument in the FDA's mouth** the same year his RTP reprise appeared — the over-conservative
  "leap of faith," the call to test-and-relax assumptions. The institutional sequel to his 1981 manifesto (file 06).